Phase 2 Brain Cancer Trial, Recruiting NCT02394626 Sponsor: Insel Gruppe AG, University Hospital Bern Condition: Brain Cancer
Back to Brain Cancer

Phase 2 Brain Cancer Trial, Recruiting

NCT02394626
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

"Who might be able to join this trial:

  • The person must be willing and able to provide written consent to participate.
  • The person must be 18 years of age or older.
  • The person must have previously had surgery to remove a glioblastoma (a type of brain tumour), confirmed by laboratory testing of the tissue.
  • The person must have already received standard radiation therapy for their glioblastoma, with or without a chemotherapy drug called temozolomide.
  • The person must be experiencing their first recurrence (return) of the tumour, as defined by specific medical imaging guidelines called RANO criteria.
  • The first recurrence must not have occurred within 3 months of finishing radiation therapy.
  • Based on brain scan (MRI) results, a specialist committee must consider it possible to fully remove the tumour that shows up on imaging, without a significant risk of causing permanent problems with speech or movement.
  • The MRI must show no involvement of specific major blood vessels in the brain (the M1 or A1 segments of certain brain arteries).
  • The MRI must show no tumour activity in the areas of the brain responsible for speech or primary movement.
  • The MRI must show no shifting of the brain's midline (the central dividing line of the brain).
  • The MRI must show no spread of the tumour to the fluid-filled spaces in the brain, no tumour in multiple separate locations, no spread along the lining of the brain or spinal cord, and no spread to the opposite side of the brain.
  • The person must have no medical reasons that would make surgery unsafe.
  • The person must have a good general level of physical functioning, as measured by a standard medical scale (a score of 70 or above on the Karnofsky Performance Scale).

Who may not be able to join:

  • The official exclusion criteria were not provided in the source document. (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying."

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Philippe Schucht, Prof. Dr. med., Dep. of Neurosurgery, Inselspital Bern

Phone: +41 31 66 4 28 65

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Insel Gruppe AG, University Hospital Bern
Registry
ClinicalTrials.gov
Start date
1 May 2015
Est. completion
1 December 2028

Where this trial is recruiting

🇦🇹 Austria 🇫🇷 France 🇩🇪 Germany 🇬🇷 Greece 🇳🇱 Netherlands 🇵🇹 Portugal 🇪🇸 Spain 🇸🇪 Sweden 🇨🇭 Switzerland

Primary endpoints

Overall survival from the date of inclusion

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov